Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Employees - 8, CEO - Oren Gilad, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -33.27, Piotroski Score(max is 10): 1, Working Capital: $11262881, Total Assets: $14321316, Retained Earnings: $-331185811, EBIT: -13671809, Total Liabilities: $2681107, Revenue: $488239

- Current Price $ - Analyst Target Price $